

1 VERMONT MEDICAL SOCIETY RESOLUTION

2 Improving the Safety of the THC-Dominant Medical Marijuana System in Vermont

3 *As adopted at the VMS Annual Meeting on November 4, 2017*

4  
5  
6 **RESOLVED**, the Vermont Medical Society reaffirms its policies “Medical Use of  
7 Marijuana” and “Cannabis Research” adopted in 2002  
8 ([http://www.vtmd.org/sites/all/themes/vms/documents/policies/2002/2002Medi](http://www.vtmd.org/sites/all/themes/vms/documents/policies/2002/2002Medical%20marijuana-cannabisresearch.pdf)  
9 [cal%20marijuana-cannabisresearch.pdf](http://www.vtmd.org/sites/all/themes/vms/documents/policies/2002/2002Medical%20marijuana-cannabisresearch.pdf)) and recommends that Medical THC-  
10 dominant Marijuana should only be available for conditions if high quality scientific  
11 studies for safety, efficacy, and side effects demonstrate that Medical THC-  
12 dominant Marijuana is safe and effective for those conditions; **and be it further**

13 **RESOLVED**, The Vermont Medical Society opposes the use of Medical THC-  
14 dominant Marijuana for the treatment of Post Traumatic Stress Disorder based on  
15 the current lack of scientific evidence; **and be it further**

16 **RESOLVED**, The Vermont Medical Society recommends that the General Assembly  
17 amend the statute governing the Vermont Marijuana Registry to require that conditions  
18 can only be added to the Marijuana Registry program after the Marijuana Review Board  
19 established under 18 VSA § 4473 reviews the evidence and makes a finding that high  
20 quality medical research demonstrates that marijuana is safe and effective for that  
21 condition; **and be it further**

22  
23 **RESOLVED**, The Vermont Medical Society recommends expanding the number of  
24 clinicians serving on the Marijuana Review Board to include at a minimum four  
25 additional physicians appointed by the Medical Practice Board; **and be it further**

26  
27 **RESOLVED**, The Vermont Medical Society recommends that the Marijuana Review  
28 Board establish a clinically-appropriate THC dose limit and concentration limit for  
29 THC-containing products sold by dispensaries, taking into consideration the 10  
30 mg maximum dose established by the FDA for FDA-approved dronabinol  
31 (Marinol); **and be it further**

32 **RESOLVED**, The Vermont Medical Society endorses NIH sponsored medical  
33 research on the potential benefits, side effects and toxicity of cannabidiol (CBD)  
34 products; **and be it further**

35 **RESOLVED**, The Vermont Medical Society recommends mandatory warning labels  
36 on Medical THC-dominant Marijuana be developed by the Marijuana Review  
37 Board, Department of Health and other appropriate agencies in conjunction with  
38 the Department of Public Safety that address dosing, side effects and potential  
39 toxicity of marijuana-containing products.